Treating disseminated fusariosis: amphotericin B, voriconazole or both?
Disseminated Fusarium infection can cause significant morbidity and mortality in immunocompromised patients. We present a case of disseminated fusariosis in a patient with neutropenic fever successfully treated using both liposomal amphotericin B and voriconazole. Combination anti-fungal therapy may be considered for such patients, particularly for those failing single-drug therapy.
Ho
Dora Y
DY
Department of Medicine, Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine, Stanford, CA 94305-5107, USA.
Lee
Jason D
JD
Rosso
Fernando
F
Montoya
Jose G
JG
D000368:Aged; D000666:Amphotericin B / Q000627:therapeutic use*; D000935:Antifungal Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D005334:Fever / Q000382:microbiology; D005670:Fusarium / Q000187:drug effects*; D006801:Humans; D016867:Immunocompromised Host; D008081:Liposomes / Q000627:therapeutic use*; D008297:Male; D009181:Mycoses / Q000188:drug therapy* / Q000382:microbiology; D009503:Neutropenia / Q000150:complications; D011743:Pyrimidines / Q000627:therapeutic use*; D016896:Treatment Outcome; D014230:Triazoles / Q000627:therapeutic use*; D065819:Voriconazole
D000935:Antifungal Agents; D008081:Liposomes; D011743:Pyrimidines; D014230:Triazoles; D000666:Amphotericin B; D065819:Voriconazole